VFY Stock Overview

Provides cryopreservation solutions in Australia. More details

VFY fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Trading at 87.9% below our estimate of its fair value

Earnings are forecast to grow 62.69% per year

Risk Analysis

Has less than 1 year of cash runway

Negative shareholders equity

Shares are highly illiquid

Makes less than USD$1m in revenue (A$37K)

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Vitrafy Life Sciences Limited Competitors

EZZ Life Science Holdings

ASX:EZZ

AU$134.3m

Proteomics International Laboratories

ASX:PIQ

AU$83.8m

Genetic Signatures

ASX:GSS

AU$143.1m

Trajan Group Holdings

ASX:TRJ

AU$158.4m

Price History & Performance

Summary of share price highs, lows and changes for Vitrafy Life Sciences
Historical stock prices
Current Share Price	AU$1.70
52 Week High	AU$2.10
52 Week Low	AU$1.65
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-14.14%

Recent updates

Shareholder Returns

	VFY	AU Life Sciences	AU Market
7D	-3.4%	1.1%	-2.7%
1Y	n/a	13.9%	6.5%

Return vs Industry: Insufficient data to determine how VFY performed against the Australian Life Sciences industry.

Return vs Market: Insufficient data to determine how VFY performed against the Australian Market.

Price Volatility

Is VFY's price volatile compared to industry and market?
VFY volatility
VFY Average Weekly Movement	n/a
Life Sciences Industry Average Movement	8.9%
Market Average Movement	8.0%
10% most volatile stocks in AU Market	16.8%
10% least volatile stocks in AU Market	3.1%

Stable Share Price: VFY's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: Insufficient data to determine VFY's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2017	22	Kate Munnings	www.vitrafy.com

Vitrafy Life Sciences Limited provides cryopreservation solutions in Australia. Its cryopreservation technology improves the cell survival of cryopreserved biological materials, such as blood platelets used to treat trauma patients, t cells used in cancer treatments, and animal sperm used in breeding and farming. The company provides smart freezing device, smart thawing device, and LifeChain, a sample quality management software platform, as well as smart blood bag and sperm packaging solution.

Vitrafy Life Sciences Limited Fundamentals Summary

How do Vitrafy Life Sciences's earnings and revenue compare to its market cap?
VFY fundamental statistics
Market cap	AU$108.54m
Earnings (TTM)	-AU$10.43m
Revenue (TTM)	AU$37.17k

2,921x

P/S Ratio

-10.4x

P/E Ratio

Is VFY overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VFY income statement (TTM)
Revenue	AU$37.17k
Cost of Revenue	AU$0
Gross Profit	AU$37.17k
Other Expenses	AU$10.46m
Earnings	-AU$10.43m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.16
Gross Margin	100.00%
Net Profit Margin	-28,051.11%
Debt/Equity Ratio	-92.9%

How did VFY perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/20 16:44
End of Day Share Price	2024/12/20 00:00
Earnings	2024/06/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vitrafy Life Sciences Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Martyn Jacobs	Bell Potter

Vitrafy Life Sciences ASX:VFY Stock Report